BPP-5a produces a potent and long-lasting NO-dependent antihypertensive effect

Therapeutic Advances in Cardiovascular Disease

Volumn 5, Issue 6, 2011, Pages 281-295

  Ianzer, Danielle ^a   Xavier, Carlos Henrique ^b   Fraga, Fabiana Costa ^b   Lautner, Roberto Queiroga ^b   Machado, Leonor Tapias ^b   Mendes, Elizabeth Pereira ^b   Guerreiro, Juliano Rodrigo ^a   Camargo, Andônio Carlos Martins ^a   Santos, Robson Augusto Souza ^c  

^a INSTITUTO BUTANTAN   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Laboratório de Hipertensão   (Brazil)

Author keywords

angiotensin I converting enzyme (ACE) inhibitor; blood pressure; bradykinin potentiating peptides; bradykinin receptors; nitric oxide

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; ARGININOSUCCINATE SYNTHASE; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ POTENTIATING PEPTIDE 5A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; OLIGOPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING ASSAY; BIOSYNTHESIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ASSAY; ENZYME INHIBITION; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR RING; VASODILATATION; WISTAR RAT;

AMINO ACID MOTIFS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BRADYKININ; ENDOTHELIUM, VASCULAR; HEART RATE; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; OLIGOPEPTIDES; PROTEIN SUBUNITS; RATS; RATS, INBRED SHR; VASODILATION; VENOMS; VIPER VENOMS;

EID: 83655172359     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944711427318     Document Type: Article

References (44)

1. Attoub S. Gaben A.M. Al-Salam S. Al Sultan M.A. John A. Nicholls M.G. et al. (2008) Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci 1138: 65–72.
2. Beny J.L. Nguyen M.N. Marino M. Matsui M. (2008) Muscarinic receptor knockout mice confirm involvement of M 3 receptor in endothelium-dependent vasodilatation in mouse arteries. J Cardiovasc Pharmacol 51: 505–512.
3. Camargo A. Ferreira S.H. (1971) Action of bradykinin potentiating factor (BPF) and dimercaprol (BAL) on the responses to bradykinin of isolated preparations of rat intestines. Br J Pharmacol 42: 305–307.
4. Camargo A.C. Ianzer D. Guerreiro J.R. Serrano S.M. (2011) Bradykinin-potentiating peptides: beyond captopril. Toxicon (Epub ahead of print).
5. Carvalho M.B. Duarte F.V. Faria-Silva R. Fauler B. da Mata Machado L.T. de Paula R.D. et al. (2007) Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension 50: 762–767.
6. Camargo A.C. Ianzer D. Guerreiro J.R. Serrano S.M. (2011) Bradykinin-potentiating peptides: beyond captopril. Toxicon (Epub ahead of print).
7. Cheung H.S. Cushman D.W. (1973) Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. Biochim Biophys Acta 293: 451–463.
8. Cotton J. Hayashi M.A. Cuniasse P. Vazeux G. Ianzer D. de Camargo A.C. et al. (2002) Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry 41: 6065–6071.
9. Erdos E.G. Tan F. Skidgel R.A. (2010) Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B 1 and B 2 receptor function. Hypertension 55: 214–220.
10. Ferreira S.H. (1965) A Bradykinin-Potentiating Factor (Bpf) Present in the Venom of Bothrops Jararca. Br J Pharmacol Chemother 24: 163–169.
11. Ferreira S.H. Bartelt D.C. Greene L.J. (1970 a) Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9: 2583–2593.
12. Ferreira S.H. Greene L.H. Alabaster V.A. Bakhle Y.S. Vane J.R. (1970 b) Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 225: 379–380.
13. Greene L.J. Camargo A.C. Krieger E.M. Stewart J.M. Ferreira S.H. (1972) Inhibition of the conversion of angiotensin I to II and potentiation of bradykinin by small peptides present in Bothrops jararaca venom. Circ Res 31(9 Suppl. 2): 62–71.
14. Guerreiro J.R. Lameu C. Oliveira E.F. Klitzke C.F. Melo R.L. Linares E. et al. (2009) Argininosuccinate synthetase is a functional target for a snake venom anti-hypertensive peptide: role in arginine and nitric oxide production. J Biol Chem 284: 20022–20033.
15. Hayashi M.A. Murbach A.F. Ianzer D. Portaro F.C. Prezoto B.C. Fernandes B.L. et al. (2003) The C-type natriuretic peptide precursor of snake brain contains highly specific inhibitors of the angiotensin-converting enzyme. J Neurochem 85: 969–977.
16. Ianzer D. Konno K. Marques-Porto R. Vieira Portaro F.C. Stocklin R. Martins d.e. Camargo A.C. et al. (2004) Identification of five new bradykinin potentiating peptides (BPPs) from Bothrops jararaca crude venom by using electrospray ionization tandem mass spectrometry after a two-step liquid chromatography. Peptides 25: 1085–1092.
17. Ianzer D. Santos R.A. Etelvino G.M. Xavier C.H. de Almeida Santos J. Mendes E.P. et al. (2007) Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca. J Pharmacol Exp Ther 322: 795–805.
18. Keim G.R. Jr Kirpan J. Peterson A.E. Murphy B.F. Hassert G.L. Jr Poutsiaka J.W. (1972) Inhibition of angiotensin I-initiated hemodynamic changes in anesthetized dogs by a synthetic nonapeptide. Proc Soc Exp Biol Med 140: 149–152.
19. Krieger E.M. Salgado H.C. Assan C.J. (1971) Greene LL, Ferreira SH: Potential screening test for detection of overactivity of renin-angiotensin system. Lancet 1: 269–271.
20. Lameu C. Hayashi M.A. Guerreiro J.R. Oliveira E.F. Lebrun I. Pontieri V. et al. (2010) The central nervous system as target for antihypertensive actions of a proline-rich peptide from Bothrops jararaca venom. Cytometry A 77: 220–230.
21. Lamping K.G. Wess J. Cui Y. Nuno D.W. Faraci F.M. (2004) Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M 2 and M 3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 24: 1253–1258.
22. Langmead C.J. Watson J. Reavill C. (2008) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117: 232–243.
23. Loyke H.F. (1977) Dose response of SQ 20, 858 in chronic renal hypertension. Pharmacol Res Commun 9: 181–186.
24. Marcic B. Deddish P.A. Jackman H.L. Erdos E.G. (1999) Enhancement of bradykinin and resensitization of its B 2 receptor. Hypertension 33: 835–843.
25. Martin J.R. (1996) Pressor effect of the putative M 1 muscarinic receptor agonist MCN-A-343 in the conscious rat. Life Sci 59: 1839–1852.
26. Morais K.L. Hayashi M.A. Bruni F.M. Lopes-Ferreira M. Camargo A.C. Ulrich H. et al. (2010) Bj-PRO-5a; a natural angiotensin-converting enzyme inhibitor; promotes vasodilatation mediated by both bradykinin B (2) and M 1 muscarinic acetylcholine receptors. Biochem Pharmacol, in press.
27. Mueller S. Gothe R. Siems W.D. Vietinghoff G. Paegelow I. Reissmann S. (2005) Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP9alpha. Peptides 26: 1235–1247.
28. Norel X. Walch L. Costantino M. Labat C. Gorenne I. Dulmet E. et al. (1996) M 1 and M 3 muscarinic receptors in human pulmonary arteries. Br J Pharmacol 119: 149–157.
29. Ondetti M.A. Cushman D.W. (1981) Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem 24: 355–361.
30. Ondetti M.A. Rubin B. Cushman D.W. (1977) Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441–444.
31. Pandey S.K. Anand-Srivastava M.B. (1996) Modulation of G-protein expression by the angiotensin converting enzyme inhibitor captopril in hearts from spontaneously hypertensive rats. Relationship with adenylyl cyclase. Am J Hypertens 9: 833–837.
32. Pinheiro S.V. Simoes e Silva A.C. Sampaio W.O. de Paula R.D. Mendes E.P. Bontempo E.D. et al. (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44: 490–496.
33. Rocha E.S.M. Beraldo W.T. Rosenfeld G. (1949) Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol 156: 261–273.
34. Sampaio W.O. Souza dos Santos R.A. Faria-Silva R. da Mata Machado L.T. Schiffrin E.L. Touyz R.M. (2007) Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49: 185–192.
35. Santos R.A. Simoes e Silva A.C. Maric C. Silva D.M. Machado R.P. de Buhr I. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258–8263.
36. Sheffler D.J. Williams R. Bridges T.M. Xiang Z. Kane A.S. Byun N.E. et al. (2009) A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol 76: 356–368.
37. Shirey J.K. Brady A.E. Jones P.J. Davis A.A. Bridges T.M. Kennedy J.P. et al. (2009) A selective allosteric potentiator of the M 1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29: 14271–14286.
38. Silva C.A. Portaro F.C. Fernandes B.L. Ianzer D.A. Guerreiro J.R. Gomes C.L. et al. (2008) Tissue distribution in mice of BPP 10c, a potent proline-rich anti-hypertensive peptide of Bothrops jararaca. Toxicon 51: 515–523.
39. Solomonson L.P. Flam B.R. Pendleton L.C. Goodwin B.L. Eichler D.C. (2003) The caveolar nitric oxide synthase / arginine regeneration system for NO production in endothelial cells. J Exp Biol 206: 2083–2087.
40. Stewart J.M. Ferreira S.H. Greene L.J. (1971) Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro. An inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II. Biochem Pharmacol 20: 1557–1567.
41. Ujhelyi M.R. Ferguson R.K. Vlasses P.H. (1989) Angiotensin-converting enzyme inhibitors: mechanistic controversies. Pharmacotherapy 9: 351–362.
42. Verano-Braga T. Figueiredo-Rezende F. Melo M.N. Lautner R.Q. Gomes E.R. Mata-Machado L.T. et al. (2010) Structure-function studies of Tityus serrulatus Hypotensin-I (TsHpt-I): A new agonist of B (2) kinin receptor. Toxicon 56: 1162–1171.
43. Verano-Braga T. Rocha-Resende C. Silva D.M. Ianzer D. Martin-Eauclaire M.F. Bougis P.E. et al. (2008) Tityus serrulatus Hypotensins: a new family of peptides from scorpion venom. Biochem Biophys Res Commun 371: 515–520.
44. Walch L. Gascard J.P. Dulmet E. Brink C. Norel X. (2000) Evidence for a M (1) muscarinic receptor on the endothelium of human pulmonary veins. Br J Pharmacol 130: 73–78.